Pharmazz, Inc.
Clinical trials sponsored by Pharmazz, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New stroke drug enters final testing phase – could improve recovery Results expected Sep 2026 (estimated)
- New drug could save lives from shock after severe bleeding Results expected Nov 2026 (estimated)
- Could a new drug save Babies' brains after oxygen loss? Results expected Nov 2026 (estimated)
- New stroke drug shows promise in major trial Results expected Sep 2027 (estimated)
-
New stroke drug enters final testing phase – could improve recovery
Disease control Recruiting nowThis study tests a drug called sovateltide in 160 people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to see if the drug helps patients recover better and is safe. Participants receive either the drug or a placebo within 24 hours of their stroke,…
Phase 4 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug could save lives from shock after severe bleeding
Disease control Recruiting nowThis study tests a new drug called LYFAQUIN (centhaquine) for people in hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. The drug aims to help restore blood pressure and improve survival when used alongside standard treatments. About 400 adult…
Phase 4 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New stroke drug shows promise in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether sovateltide, a drug that stimulates ETB receptors, can improve recovery after an acute ischemic stroke. About 514 adults aged 18-80 will receive either sovateltide or a placebo alongside standard care. The main goal is to see if more patients achi…
Phase 3 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a new drug save Babies' brains after oxygen loss?
Disease control Recruiting nowThis study tests a drug called sovateltide in newborns with brain injury from lack of oxygen at birth (hypoxic-ischemic encephalopathy). The drug aims to help the brain repair itself. About 40 full-term babies will receive either sovateltide or a placebo, along with standard cool…
Phase 2 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC